Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 7/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.73 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.69 |
| ▸ | PCSK9 | Q8NBP7 | 3/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715806 | 0.84 | MPO (0.81) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL1968447 | 0.84 | MPO (1.00) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL25882598 | 0.84 | MPO (0.60) | MPOSLC6A4GPR84HTR2AMAPT | |
| SCHEMBL13715343 | 0.83 | MPO (0.73) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL14720635 | 0.83 | MPO (0.73) | MPOSLC6A4GPR84PCSK9HTR2A | |
| Hydrochloric Acid SCHEMBL23091149 | 0.83 | MPO (0.97) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL27503238 | 0.83 | MPO (0.73) | MPOSLC6A4GPR84PCSK9HTR2A | |
| SCHEMBL5477550 | 0.82 | MPO (0.49) | MPOSLC6A4GPR84HTR2AMAPT | |
| SCHEMBL10252339 | 0.82 | MPO (0.49) | MPOSLC6A4GPR84HTR2AMAPT | |
| SCHEMBL29005984 | 0.82 | GPR84 (1.00) | MPOSLC6A4GPR84PCSK9HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446122-B2 | Substituted indole derivatives | CEPHALON, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7314886-B2 | Tetrahydropyrano-indole derivatives | CEPHALON, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070244180-A1 | Substituted indole derivatives | SALMEDIX, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060166947-A1 | Multiple myeloma treatments | DANA-FARBER CANCER INSTITUTE, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | SALMEDIX, INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680428-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1673373-A2 | INDOLE DERIVATIVES | Salmedix, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005033112-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033113-A2 | INDOLE DERIVATIVES | CEPHALON, INC (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244180-A1 | Substituted indole derivatives | IDO1, IDO2, HTR3A | MPO 2633/4885SLC6A4 27/4885GPR84 3941/4885 |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | IL6, OPRK1, PTGES3 | MPO 67/4885SLC6A4 2503/4885GPR84 3597/4885 |
| US-20060166947-A1 | Multiple myeloma treatments | BCL6, MCL1, BCL6B | MPO 4594/4885SLC6A4 1619/4885GPR84 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.